Target Price | €163.20 |
Price | €112.80 |
Potential | 44.68% |
Number of Estimates | 21 |
21 Analysts have issued a price target Merck 2026 . The average Merck target price is €163.20. This is 44.68% higher than the current stock price. The highest price target is €204.75 81.52% , the lowest is €108.07 4.19% . | |
A rating was issued by 24 analysts: 19 Analysts recommend Merck to buy, 3 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Merck stock has an average upside potential 2026 of 44.68% . Most analysts recommend the Merck stock at Purchase. |
21 Analysts have issued a sales forecast Merck 2025 . The average Merck sales estimate is €22.0b . This is 3.06% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €23.4b 9.90% , the lowest is €20.8b 2.33% .
This results in the following potential growth metrics:
2024 | €21.2b | 0.78% |
---|---|---|
2025 | €22.0b | 3.84% |
2026 | €22.8b | 3.74% |
2027 | €23.7b | 3.93% |
2028 | €23.9b | 0.99% |
2029 | €25.0b | 4.50% |
2030 | €25.1b | 0.48% |
2031 | €25.4b | 0.98% |
2032 | €27.4b | 8.11% |
19 Analysts have issued an Merck EBITDA forecast 2025. The average Merck EBITDA estimate is €6.2b . This is 6.07% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €7.2b 22.65% , the lowest is €5.6b 4.37% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | €4.9b | 3.42% |
---|---|---|
2025 | €6.2b | 26.53% |
2026 | €6.7b | 7.05% |
2027 | €7.0b | 4.37% |
2028 | €7.1b | 2.21% |
2029 | €7.5b | 4.63% |
2030 | €7.7b | 3.86% |
2031 | €7.7b | 0.67% |
2032 | €7.9b | 2.17% |
2024 | 23.31% | 2.62% |
---|---|---|
2025 | 28.40% | 21.85% |
2026 | 29.31% | 3.20% |
2027 | 29.43% | 0.41% |
2028 | 29.79% | 1.22% |
2029 | 29.82% | 0.10% |
2030 | 30.83% | 3.39% |
2031 | 30.32% | 1.65% |
2032 | 28.66% | 5.47% |
19 Merck Analysts have issued a net profit forecast 2025. The average Merck net profit estimate is €4.1b . This is 44.32% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €4.6b 62.06% , the lowest is €3.6b 26.30% .
This results in the following potential growth metrics and future Net Margins:
2024 | €2.8b | 1.66% |
---|---|---|
2025 | €4.1b | 46.40% |
2026 | €4.5b | 9.48% |
2027 | €4.7b | 5.80% |
2028 | €4.6b | 1.82% |
2029 | €5.0b | 7.13% |
2030 | €4.9b | 0.96% |
2031 | €5.2b | 7.00% |
2032 | €5.4b | 2.04% |
2024 | 13.13% | 2.42% |
---|---|---|
2025 | 18.51% | 41.01% |
2026 | 19.53% | 5.51% |
2027 | 19.88% | 1.79% |
2028 | 19.33% | 2.77% |
2029 | 19.81% | 2.48% |
2030 | 19.53% | 1.41% |
2031 | 20.69% | 5.94% |
2032 | 19.53% | 5.61% |
19 Analysts have issued a Merck forecast for earnings per share. The average Merck EPS is €9.35 . This is 44.29% higher than earnings per share in the financial year 2024. The highest EPS forecast is €10.50 62.04% , the lowest is €8.18 26.23% .
This results in the following potential growth metrics and future valuations:
2024 | €6.39 | 1.69% |
---|---|---|
2025 | €9.35 | 46.32% |
2026 | €10.24 | 9.52% |
2027 | €10.83 | 5.76% |
2028 | €10.63 | 1.85% |
2029 | €11.39 | 7.15% |
2030 | €11.28 | 0.97% |
2031 | €12.07 | 7.00% |
2032 | €12.32 | 2.07% |
Current | 17.41 | 30.99% |
---|---|---|
2025 | 12.06 | 30.72% |
2026 | 11.02 | 8.62% |
2027 | 10.42 | 5.44% |
2028 | 10.61 | 1.82% |
2029 | 9.90 | 6.69% |
2030 | 10.00 | 1.01% |
2031 | 9.34 | 6.60% |
2032 | 9.16 | 1.93% |
Based on analysts' sales estimates for 2025, the Merck stock is valued at an EV/Sales of 2.59 and an P/S ratio of 2.27 .
This results in the following potential growth metrics and future valuations:
Current | 2.67 | 24.79% |
---|---|---|
2025 | 2.59 | 3.12% |
2026 | 2.49 | 3.60% |
2027 | 2.40 | 3.78% |
2028 | 2.38 | 0.98% |
2029 | 2.27 | 4.31% |
2030 | 2.26 | 0.48% |
2031 | 2.24 | 0.97% |
2032 | 2.07 | 7.51% |
Current | 2.33 | 26.39% |
---|---|---|
2025 | 2.27 | 2.97% |
2026 | 2.18 | 3.60% |
2027 | 2.10 | 3.78% |
2028 | 2.08 | 0.98% |
2029 | 1.99 | 4.31% |
2030 | 1.98 | 0.48% |
2031 | 1.96 | 0.97% |
2032 | 1.81 | 7.50% |
Analyst | Rating | Action | Date |
---|---|---|---|
REDBURN ATLANTIC |
Buy
➜
Buy
|
Unchanged | Apr 06 2025 |
DZ BANK |
Buy
➜
Buy
|
Unchanged | Apr 01 2025 |
DAY BY DAY |
Sell
➜
Sell
|
Unchanged | Mar 30 2025 |
HSBC |
Buy
➜
Buy
|
Unchanged | Mar 23 2025 |
EQUITA SIM |
Buy
➜
Buy
|
Unchanged | Mar 16 2025 |
ODDO BHF |
Buy
➜
Buy
|
Unchanged | Mar 10 2025 |
JEFFERIES |
Buy
➜
Buy
|
Unchanged | Mar 05 2025 |
Analyst Rating | Date |
---|---|
Unchanged
REDBURN ATLANTIC:
Buy
➜
Buy
|
Apr 06 2025 |
Unchanged
DZ BANK:
Buy
➜
Buy
|
Apr 01 2025 |
Unchanged
DAY BY DAY:
Sell
➜
Sell
|
Mar 30 2025 |
Unchanged
HSBC:
Buy
➜
Buy
|
Mar 23 2025 |
Unchanged
EQUITA SIM:
Buy
➜
Buy
|
Mar 16 2025 |
Unchanged
ODDO BHF:
Buy
➜
Buy
|
Mar 10 2025 |
Unchanged
JEFFERIES:
Buy
➜
Buy
|
Mar 05 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.